Biocardia announces positive dsmb review and recommendation to continue phase iii pivotal cardiamp cell therapy heart failure study as designed

Sunnyvale, calif., feb. 14, 2022 (globe newswire) -- biocardia®, inc.  [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent data safety monitoring board (dsmb) has completed its prespecified data review for the ongoing phase iii pivotal cardiamp™ cell therapy heart failure trial (clinicaltrials.gov identifier: nct02438306), just one week after receiving breakthrough device designation from the fda. the dsmb based its review on all available data for the 108 patients enrolled with an additional six crossover patient procedures in the trial to date. the dsmb performed a risk-benefit assessment, indicated no significant safety concerns, and recommended that the study continue as designed.
BCDA Ratings Summary
BCDA Quant Ranking